Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
FAIL · Does not pass the screen
9.15 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 08:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price9.15 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 9.15 against the desk's fair-value range, base estimate 18.30, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price9.15 USD
Fair value18.30
Ethical score70.0/100
Our investment reviews on this name
2026-10-21Read Markdown11.16-18.0% to today ✓Distribution gives way to Markdown after a 6% rise in 10 days
2026-10-11Read Distribution10.55-13.3% to today ✓Markup gives way to Distribution after an 8% slide in 8 weeks
2026-08-14Read Markup11.52-20.6% to today Markdown gives way to Markup after a 21% rise in 6 weeks
2026-07-02Read Markdown9.56-4.3% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Telix Pharmaceuticals Limited holds its Markdown at $9.15. Consolidating, no directional conviction, held for 4 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 4 days
Price at the screen
$9.15
Valuation
111.60 trailing · -415.15 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.56
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
40.13%
Below 33%
Interest-bearing debt is 40.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
23.29%
Below 49%
Money owed to the company is 23.3% of assets, under the 49% limit.
Pass
Revenue purity
0.72%
Below 5%
Only 0.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Telix Pharmaceuticals's business is in a permissible area, but its interest-bearing debt is about 40% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TLX's ethical verdict changes
Today TLX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus Strong Buy. The average target sits +136% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Radiopharma Growth Story Still Priced For Perfection
Imagine a lab racing to turn radioactive tracers into approved cancer treatments. The first approvals land and revenue jumps 49 percent, yet the company still posts a negative 1 percent profit margin and negative 2 percent return on equity. Telix clears our ethical screen, yet the forward multiple of 45.9 times leaves almost no room for the usual biotech setbacks.
We pass because the valuation already bakes in strong analyst targets near 21 dollars while the business remains unprofitable. A 25 percent margin of safety to our fair value of 13.08 dollars is not enough when commercial-stage radiopharma still carries binary trial and regulatory risk. The unknown moat offers no extra cushion.
High growth in a new modality is real, but paying premium multiples for losses has burned investors before. Currency and reimbursement hurdles in Australia and abroad add further volatility. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Australia and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TLX trades on Nasdaq (the company is based in Australia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-21Markdown · changed$11.16+5.8%Entry 8
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 11% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $21. Insiders have been net buyers over the past quarter.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 16.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $21. Insiders have been net buyers over the past quarter.
2026-10-02Markup$12.59+13.1%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $21. Insiders have been net buyers over the past quarter.
2026-09-14Markup$11.13-3.4%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $21.
2026-08-14Markup · changed$11.52+20.5%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $21.
2026-07-18Markdown$9.56+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (4 analysts) rates it strong buy, with a mean price target of $21.
2026-07-03Markdown$9.56+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markdown$9.56Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.